TY - JOUR
T1 - Carbon nanomaterials and amyloid-beta interactions
T2 - potentials for the detection and treatment of Alzheimer's disease?
AU - Mohajeri, Mohammad
AU - Behnam, Behzad
AU - Barreto, George E.
AU - Sahebkar, Amirhossein
N1 - Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/5
Y1 - 2019/5
N2 - Carbon-based nanomaterials have unique physicochemical properties relevant to the diagnosis and treatment of various diseases. There have been many reports indicating that carbon nanomaterials (CNMs) can interact and perturb biomolecules such as proteins and amyloid structures. This review is an attempt to reflect the role of CNMs in the treatment and detection of Alzheimer's disease (AD). The potential of CNMs in the field of neuroscience has also been reviewed. The exposure to CNMs ends up with effective radical and peptide scavenging structures, which, in turn, inhibit further formation and progression of amyloid fibrils. However, the effect of CNMs on initial nucleation and lag phase in this process may promote fibrillation. We have discussed the controversy that whether CNMs promote or inhibit the formation of amyloid beta (Aβ) fibrils to help preventing their toxicity or enhancing their therapeutic effects.
AB - Carbon-based nanomaterials have unique physicochemical properties relevant to the diagnosis and treatment of various diseases. There have been many reports indicating that carbon nanomaterials (CNMs) can interact and perturb biomolecules such as proteins and amyloid structures. This review is an attempt to reflect the role of CNMs in the treatment and detection of Alzheimer's disease (AD). The potential of CNMs in the field of neuroscience has also been reviewed. The exposure to CNMs ends up with effective radical and peptide scavenging structures, which, in turn, inhibit further formation and progression of amyloid fibrils. However, the effect of CNMs on initial nucleation and lag phase in this process may promote fibrillation. We have discussed the controversy that whether CNMs promote or inhibit the formation of amyloid beta (Aβ) fibrils to help preventing their toxicity or enhancing their therapeutic effects.
KW - Alzheimer's disease
KW - Amyloid beta fibril
KW - Carbon nanomaterials
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=85063760662&partnerID=8YFLogxK
U2 - 10.1016/j.phrs.2019.03.023
DO - 10.1016/j.phrs.2019.03.023
M3 - Review article
C2 - 30943430
AN - SCOPUS:85063760662
SN - 1043-6618
VL - 143
SP - 186
EP - 203
JO - Pharmacological Research
JF - Pharmacological Research
ER -